β-Lactamases Responsible for Resistance to Expanded-Spectrum Cephalosporins in Klebsiella pneumoniae , Escherichia coli , and Proteus mirabilis Isolates Recovered in South Africa
- 1 June 1998
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 42 (6), 1350-1354
- https://doi.org/10.1128/aac.42.6.1350
Abstract
Although resistance to the expanded-spectrum cephalosporins among members of the family Enterobacteriaceae lacking inducible β-lactamases occurs virtually worldwide, little is known about this problem among isolates recovered in South Africa. Isolates of Klebsiella pneumoniae , Escherichia coli , and Proteus mirabilis resistant to expanded-spectrum cephalosporins recovered from patients in various parts of South Africa over a 3-month period were investigated for extended-spectrum β-lactamase production. Antibiotic susceptibility was determined by standard disk diffusion and agar dilution procedures. Production of extended-spectrum β-lactamases was evaluated by using the double-disk test, and the β-lactamases were characterized by spectrophotometric hydrolysis assays and an isoelectric focusing overlay technique which simultaneously determined isoelectric points and general substrate or inhibitor characteristics. DNA amplification and sequencing were performed to confirm the identities of these enzymes. The P. mirabilis and E. coli isolates were found to produce TEM-26-type, SHV-2, and SHV-5 extended-spectrum β-lactamases. An AmpC-related enzyme which had a pI of 8.0 and which conferred resistance to cefoxitin as well as the expanded-spectrum cephalosporins was found in a strain of K. pneumoniae . This is the first study which has identified organisms producing different extended-spectrum β-lactamases from South Africa and the first report describing strains of P. mirabilis producing a TEM-26-type enzyme. The variety of extended-spectrum β-lactamases found among members of the family Enterobacteriaceae isolated from major medical centers in South Africa is troubling and adds to the growing list of countries where these enzymes pose a serious problem for antimicrobial therapy.Keywords
This publication has 32 references indexed in Scilit:
- Treatment failure due to extended spectrum βlactamaseJournal of Antimicrobial Chemotherapy, 1996
- New variant of TEM-10 beta-lactamase gene produced by a clinical isolate of proteus mirabilisAntimicrobial Agents and Chemotherapy, 1995
- TEM- and SHV-derived extended-spectrum β-lactamases: relationship between selection, structure and functionJournal of Antimicrobial Chemotherapy, 1995
- Extended-spectrum β-lactamase in Proteus mirabilisJournal of Antimicrobial Chemotherapy, 1994
- Convergent evolution of TEM-26, a β-lactamase with extended-spectrum activityJournal of Antimicrobial Chemotherapy, 1994
- Multiresistant Klebsiella pneumoniae in a neonatal nursery: the importance of maintenance of infection control policies and procedures in the prevention of outbreaksJournal of Hospital Infection, 1992
- Outbreak of ceftazidime resistance due to a novel extended-spectrum beta-lactamase in isolates from cancer patientsAntimicrobial Agents and Chemotherapy, 1992
- Characterization of the plasmid mediated β-lactamase BIL-1Journal of Antimicrobial Chemotherapy, 1992
- Extended-spectrum beta-lactamasesAntimicrobial Agents and Chemotherapy, 1989
- The Use of Analytical Isoelectric Focusing for Detection and Identification of -LactamasesJournal of General Microbiology, 1975